The Latest Regenerative Medicine Articles from Streetwise Reports


Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

  ()
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. read more >

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

Research Report
  ()
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. read more >

Three COVID-19 Patients Treated with PLX Cells

Research Report
  ()
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. read more >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

Research Report
  ()
The compelling aspects of this life sciences story are presented in a Dawson James report. read more >

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

  ()
Proteostasis Therapeutics' shares traded higher after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. read more >
Showing Results: 1 to 5 of 5

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts